Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Biodexa Pharmaceuticals PLC

BDRX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.52

▼ -2.56%

Market Cap $1.56M · Vol 1.37K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.56M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

47.62

Momentum

Beta

1.32

vs Market

52W High

$59.40

97.44% below

52W Low

$1.02

49.02% above

Volume

1.37K

Avg 28.31K

P/B

0.33

Price-to-book

ROE

N/A

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Biodexa Pharmaceuticals PLC (BDRX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BDRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.30%

-33.04%

-55.29%

-71.85%

YTD

-86.61%

-95.63%

-99.98%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-8,601,107.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-39.38% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	102.91B

Technical Indicators

50-Day SMA	$2.31
200-Day SMA	$8.95
RSI (14)	47.62
Beta	1.32
52-Week High	$59.40
52-Week Low	$1.02

Volume Today	1.37K
Avg Daily Volume (30D)	28.31K
Relative Volume	0.05x
Volatility (10D)	78.63
Volatility (30D)	85.80
Free Float	100.00%

Analyst Consensus

N/A

Current Price $1.52

Mean Target $10.00

52W Low$1.02 52W High$59.40

Current

Target

$1.02 $59.40

Current Analyst target

+557.89% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00BLVW3G4

ISINUS59564R8723

CountryUnited Kingdom

Sub-IndustryBio Therapeutic Drugs

Earnings DateMay 15, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.